ASH 2021 | Maintenance venetoclax and 5-azacytidine in patients with AML
Alexandre Bazinet
• 7 Dec 2021
Remission from AML is successful with current therapies, but relapse rates remain high among patients. Alexandre Bazinet, MD, McGill University, Montreal, Canada, discusses results from the Phase II trial (NCT04062266) of low-dose 5-azacytidine and venetoclax as maintenance therapy in patients with acute myeloid leukemia (AML). Patients responded well to the maintenance treatment strategy, especially patients with favorable-risk AML subtypes such as NPM1- or IDH1/2-mutated AML. Dr Bazinet additionally highlights the need for further follow-up from the preliminary results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
